Skip to content

Grupo de Investigación en Atención Farmacéutica

Inicio Contactar Buscar e-Formación e-Investigación Daderweb

GIAF - UGR (CTS 131)

Universidad de Granada
(Facultad de Farmacia)
Campus Universitario de Cartuja

958 24 19 31

giaf-ugr@atencionfarmaceutica-ugr.es

Estás aquí: Inicio-
Efectividad de un protocolo normalizado de dispensación en farmacia comunitaria
lunes, 10 de octubre de 2016

Effectiveness of a protocolized dispensing service in community pharmacy for improving patient medication knowledge

Abaurre-Labrador R, Maurandi-Guillén MD, García-Delgado P , Moullin JC, Martínez-Martínez F , García-Corpas JP .

Background

Sufficient patient medication knowledge is essential for appropriate use. The dispensing service provided in community pharmacies is one method that may be used to educate patients on their medications.

Objective

To compare the effectiveness of protocolized dispensing (following a dispensing protocol that includes standardized patient education), with the effectiveness of traditional dispensing (provision of medication without standardized patient education and information provided only if directly requested), for improving patient medication knowledge.

Method

Pre-post quasi-experimental study of patients or caregivers over 18 years of age requesting one or more medications for their own use or for others. The intervention consisted of using a protocolized process for dispensing medicines in a community pharmacy. The association between the dispensing effectiveness (patient medication knowledge pre and post dispensing) and predictor variables was studied using a multivariate binary logistical regression model.

Results

In total 661 participant medication requests were included in the study. Protocolized dispensing was more effective than traditional dispensing for improving medication knowledge (OR 2.390; 95 % CI 1.373–1.162).

Conclusion

As a means to improve patient medication knowledge it may be recommended that protocolized dispensing processes should be developed, evaluated and implemented with the ultimate aim of improving the appropriate use of medicines.

Keywords

Community pharmacy services, Dispensing Patient medication knowledge, Spain.
 

 

 
Efectividad y seguridad de genérico de acavir/lamivudine y efavirenz en pacientes vih naïve
jueves, 06 de octubre de 2016

Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011–2012."

Jaime Galindo, Pedro Amariles , Héctor F. Mueses-Marín, Jaime A. Hincapié, Sebastián González-Avendaño, Ximena Galindo-Orrego.

Abstract

Background

Generic drug policies are often associated with concerns about the quality and effectiveness of these products. Phase IV clinical trials may be a suitable design to assess the effectiveness and safety of generic drugs. The objective of this study was to describe the effectiveness and the safety of the generic abacavir/lamivudine and efavirenz in treatment-naïve HIV-infected patients.

Methods

A monocentric, nonrandomized, open-label, phase IV study in treatment naïve HIV-infected patients 18 years or older with indication to receive abacavir/lamivudine and efavirenz were recruited from a program that provides comprehensive outpatient consultation and continuing care. The primary end-point was to achieve viral load <40 copies/mL at 12 months after baseline to assess effectiveness. Secondary end-point of the study were 1) to asses increasing in T-CD4 lymphocytes levels as accompaniment to asses effectiveness, and 2) to assess both gastrointestinal, skin, and central nervous system symptoms, and lipid profile, cardiovascular risk, renal, and hepatic function as safety profile. Data were determined at baseline, 3, 6, and 12 months. Close clinical monitoring and pharmaceutical care were used for data collection. Wilcoxon matched-pairs signed-rank test was used to compare proportions or medians.

Results

Sixty patients were invited to participate in the study; 42 were enrolled and 33 completed the follow-up. Of the nine patients excluded from the study, only one was withdrawn due to adverse events. At 12 months, 31 of 42 patients (73.8 % in intention-to-treat analysis) achieved a viral load of HIV1 RNA <40 copies/mL. There was a significant increase (172 cells/mm3) in the median for CD4 T lymphocyte count. The adverse events were mild and met the safety profile for this antiretroviral regimen, mainly of central nervous system symptoms, skin rash, lipid abnormalities, and an increase of 2 % in the median of the percentage of cardiovascular risk.

Conclusions

The clinical outcomes of generic version of abacavir/lamivudine and efavirenz in HIV treatment naïve patients showed the expected safety and effectiveness profile of proprietary ARV drugs.

Trial registration

Registro Público Cubano de Ensayos Clínicos (RPCEC) ID: RPCEC00000202. Registered 19 November 2015.

Keywords

HIV/AIDS Generic drugs Antiretroviral drugs Phase IV study
 

 

 

 
CONVOCATORIA DE PLAZAS DE INVESTIGADOR COLABORADOR
lunes, 14 de marzo de 2016
El Grupo de Investigación en Atención Farmacéutica CTS131 de la Universidad de Granada, convoca plazas de Investigadores/as colaboradores/as para la participación en proyectos de investigación durante los cursos académicos 2016-2017, 2017-2018.
Se valorará:
- Conocimientos en Atención Farmacéutica
- Conocimientos en Investigación
- Dominio de lengua inglesa
- Manejo de herramientas informáticas
Los interesados enviarán Curriculum Vitae y situación laboral actual a
Fecha límite de envío 31 de marzo de 2016
 
<< Inicio < Anterior 1 2 3 4 5 6 7 8 9 10 Siguiente > Final >>

Resultados 9 - 12 de 133
Facultad de Farmacia - Universidad de Granada Universidad de Granada Junta de Andalucía
FEDER Oficina de Transferencia de Resultados de investigación
 
 
premios_foro_GIAF-UGR

Formulario de acceso





cursoHerramientasInformaticasFarmacia
MASTER 7
catedra
ars_link
 
[+]
  • Wide screen resolution
  • Auto width resolution
  • Increase font size
  • Decrease font size
  • Default font size